Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 Long-term Safety in PNH
NCT04702568Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Dec 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Treatment Emergent Adverse Events at Week 147. Started Dec 2020; status: terminated.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04702568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702568.